SMOORE
23.9.2021 13:17:15 CEST | Business Wire | Press release
SMOORE, a global leader in offering vaping technology solutions, today has made its mark at The Global Tobacco & Nicotine Forum (GTNF) 2021. Senior Vice President of SMOORE and President of FEELM, the flagship atomization tech brand belonging to SMOORE, Frank Han makes the keynote speech to outline SMOORE’s mission of “atomization making life better.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005511/en/
The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. The annual industry conference brings together key stakeholders from around the world, including global tobacco companies, vaping brands, scientists, public health experts, NGOs and policymakers.
In his speech, Frank Han calls upon all stakeholders of the industry to join the mission of “atomization making life better”, promoting the evolution of atomization ecosystem . He asserts that policymakers and NGOs should take the lead in institutional innovations to promote the healthier industry development and more balanced regulations, embracing vaping as a strategy to improve public health while safeguarding against youth vaping. Global media could also involve more people in the unbiased public dialogue on vaping.
Moreover, industry leaders should work together to build up more comprehensive industry standards. As one of the key industry standard setters, SMOORE has developed its vapor and material safety standards, which involve over 300 physical and chemical tests. These standards have also covered all of PMTA tests and the safety evaluation of over 50 atomization materials, thereby guaranteeing industry-leading product quality.
In terms of product innovation , Frank Han indicates that the underlying technology of vaping—atomization, has showed promising prospects in other fields, such as healthcare. With one of its R&D focus on the atomization application in healthcare, SMOORE has made significant progress on the research of atomized medication in the past three years.
“In the near future, more and more people will inhale medicines or vaccines with atomization devices. It could help the world pull through the pandemic,” said Frank Han.
According to Frank Han, SMOORE’s innovations are based on its insights into global consumers’ requirements and the commitment to improving user experience, which is the company’s first principle of product development. Based on the principle, SMOORE launched the world’s first Taste Evaluation Model in 2020, covering 4 dimensions and 51 indexes, so as to establish a scientific system to evaluate vaping tastes.
Moreover, Frank Han points out that scientific innovation is the driving force of the industry’s evolution. Industry pioneers are constantly committed to the cross-disciplinary fundamental research of “atomization science”, to explore the mechanism of atomization.
As the world’s leading atomization tech platform, SMOORE has recruited R&D experts from different backgrounds and built up 7 global research centers around the world. In addition to in-house R&D resources, SMOORE has partnered with top universities to leverage the latest scientific discoveries and transform them into cutting–edge applied technologies.
The industry is also embracing intelligent manufacturing to improve resource efficiency. For example, SMOORE introduced the first fully automated pod production line in the world. Now, a single line of SMOORE can produce 7,200 standard vaporizers per hour.
In partnership with clients, SMOORE has also adopted sustainable practices in all stages of product development, especially manufacturing, so as to fulfill its commitment to reducing carbon footprint.
“Innovation and sustainability are the ideas to which the whole industry has been adhering, since the advent of vaping. The two ideas share a common goal, that is ‘atomization making life better’, which echoes SMOORE’s corporate mission,” said Frank Han.
Committed to the mission of “Atomization making life better”, SMOORE will continue to discover more diversified atomization methods and more advanced technology roadmap while jointly promoting a more inclusive dialogue mechanism along with partners from different sectors.
About SMOORE
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.
About FEELM
FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world. The accumulated sales volume of FEELM has surpassed 3 billion pieces per year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
